Issue link: http://osercommunicationsgroup.uberflip.com/i/265900
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 1 3 , 2 0 1 3 5 2 The fact is, we've been a little bit fragmented in how we approach our cus- tomers. That's changing now as we lever- age our total platform of trusted brands to become the partner of choice for growth. To make this possible, Newell Rubbermaid recently underwent a reor- ganization that will unlock tremendous trapped costs that we are converting into fuel for growth. Our new "Growth Game Plan" means more money for marketing and merchandising, and more investment in innovation and product development. For example, we recently announced that we're building a new state-of-the art design center to accelerate the product development process. As the new leader of our customer development organization, I am building a team of great people who are commit- ted to becoming better partners to our retail customers. As a first step, we recently invested in a new group that is 100 percent focused on shopper market- ing, which will help us better customize programs for bigger impact in-store. In my experience, the single best way to accelerate growth is through out- Newell Rubbermaid (Cont'd. from p. 1) standing customer collaboration where we work together as one (manufacturer and retailer together) with the overarch- ing objective of delighting shoppers. To do this, I'd like to partner more closely, collaborating with more lead time so together we can customize the mix to develop differentiated programs for you that drive sustainable growth. We will also bring more marketplace insights to the table. You are the expert on your shopper– but we are the experts on our category, and utilizing these together can help us drive store traffic and increase basket size. The biggest lesson I've learned in my career is that it pays to collaborate and invest in your customer. Newell Rubbermaid is unlocking new fuel for growth, and we will use it to develop closer customer partnerships that create more value across the total enterprise. It's a huge opportunity for us, and we look forward to working closely with our part- ners to achieve this. We still have a lot work to do, but we aspire to be your part- ner of choice for growth. For more information, visit booth 5260 or go online to www.newellrubbermaid.com. Laboratories focused on meeting and exceeding patient needs every day. Roxane Laboratories operates as the research and development and sales and marketing arms of Boehringer Ingelheim's multi-source pharmaceutical business. Today, Roxane markets more than 100 medications in 280 package sizes. Roxane is committed to expanding its line of multisource pharmaceutical products that are formatted as bulk and unit-dose package configurations for liq- uids and solids; coated, sustain-released and controlled-release tablets; nasal sprays; topical solutions; cytotoxics; and CII narcotics. Advancements in con- trolled substances, sustain-released items, potent compounds, unit doses and bulk packaging all reflect our dedication to provide customers with innovative, technically complex products from our FDA-approved facilities. The team at Roxane understands how every aspect of its business can affect your patients' lives—Roxane provides quality products for a range of clinical areas and have a team of highly skilled researchers and patent-experienced attor- neys who are tasked with putting afford- able generic treatments on the market and into your hands as soon as possible. Roxane's pursuit of high-quality products and service is also accompanied by a lean manufacturing model staffed by a skilled, flexible workforce. This innova- tive manufacturing and business practice allows for quick shifts in production based on opportunities and business needs. As always, Roxane maintains impressive lev- els of safety, quality and compliance. Quality, safe, and affordable growth has continued for Roxane in 2012. The company is proud to have launched these eleven new generic products: Dipyridamole Tablets, USP; Quetiapine Fumarate Tablets; Tinidazole Tablets; Hydromorphone Hydrochloride Oral Solution, USP; Nevirapine Tablets; Nevirapine Oral Suspension; Montelukast Sodium Tablets; Montelukast Sodium Chewable Tablets; Oxcarbazepine Oral Suspension; Irbesartan and Hydrochlorothiazide Tablets, USP; and Irebesartan Tablets, USP. Visit Roxane during the 2013 NACDS Total Store Expo at booth 4629. For more information, visit www.roxane.com to view a complete product catalog, and reach Roxane's TouchPoint Customer Service Center 24/7 for information about your account and order status. Roxane (Cont'd. from p. 1) manufacturer and distributor of its own health and beauty care products. Sales of Majestic products continued to increase causing a need for additional management personnel. To that end, Larry Fishman was brought aboard in 1970 as Vice President. In 1979, Majestic launched Dentemp Custom, the first O-T- C temporary dental repair to re-cement loose caps or replace lost fillings. In 1985, Larry Fishman was appointed President. Recognizing the need for exemplary customer service, Nilda L. Oyola was appointed head of customer relations in 1990. All product lines continued to grow throughout the '80s and into the '90s. In 1993, in an effort to concentrate on the burgeoning niche OTC drug products market, Majestic sold its hair coloring and professional hair care product lines. With its focus firmly set on this new market, Majestic launched several new products, including Dentemp O.S., the No. 1-sell- ing dental repair for both loose caps and lost fillings, Repair-It denture repair kit, Recapit, for loose caps, Refilit, for lost fillings, Dentool Jr, a 2-in-1 professional quality dental tool including a scraper and a pick, Mandelay climax control gel for men, Femystique feminine arousal gel and KutKit Styptic Swabs to instantly stop the bleeding from shaving nicks and minor cuts and scrapes. In 2005, Majestic bought Sword Floss, the original dispos- able floss/pick. In 2006, Majestic intro- duced Clean-It denture wipes, the easy way to remove adhesive from dentures, gums and the upper palate. In 2007, Nilda Oyola was promoted to the position of Marketing Coordinator and Assistant to the President. More recently, Majestic has contin- ued to innovate with Proxi-Plus, the only interdental brush with a bonus flosser on the other end, Reline-It denture reliner and Senzzzzz Away, the only tooth desensitizer that eliminates sensitivity to cold, sweets and heat for six months with just one application. In 2010, Wendy Rosenblum was promoted to Office Manager. In 2011, David Fishman came to Majestic as Executive VP and Melinda Cali was hired as Administrative Assistant. In 2012, Nilda Oyola was promoted to VP Sales. For over 60 years, Majestic has pro- moted a family atmosphere with the majority of its employees having now been with the company for over six years. Majestic's commitment to provid- ing innovative and high quality products at reasonable prices, supported by unpar- alleled customer service, continues to be the cornerstone of Majestic's growth. For more information, visit booth 3154 at the NACDS Total Store Expo or go online to www.majesticdrug.com. Majestic Drug Co. (Cont'd. from p. 1) and pharmacy profit. Medication synchronization drives adherence by providing patients with all their medication during one visit to the pharmacy and eliminates the probability of a drug getting left behind or forgotten to be picked up. MarkeTouch Media's Optimum MedSync works by evaluating each patient profile and selecting the patients that are most likely to benefit from synchronization. Multiple factors are taken into consideration, including clients' operational goals, patient needs, and disease states. Optimum MedSync is a service that offers clients a clear advantage when it comes to aligning their patients refill dates, and it is designed to drive patient adherence. The solution provides data mining tools to assist subscribing phar- macies in meeting quality metrics. Enhancing a pharmacy's performance within the CMS Quality ratings can drive higher reimbursements under the pay- for-performance models. Rather than just being another tech- nology platform, MarkeTouch Media works with its client to align the solution to clinical and operational goals. The RxTouch sync engine is flexible enough to allow clients to determine patient eli- gibility into the program and automati- cally calculates optimum sync date based on an algorithm of weighted factors that is established based on internal influ- ences. The solution's automated process- es are designed to be customized by clients to optimize patient satisfaction, MarkeTouch Media (Cont'd. from p. 1) patient results, and client operations. Optimum MedSync provides an easy way to document and drive the clinical outcomes of various patient populations. Communication tools facilitate direct patient interaction, which according to NCPA "is the single strongest predictor of individual med- ication adherence" (2013 Adherence Report Card). Studies have shown that direct pharmacist interaction is key to assisting patients in taking their med- ication correctly and length of therapy directly influences patient's clinical outcomes. [ASHP Midyear Clinical Presentation, December 4, 2011, "Partnership for Patients: A Collaboration to Improve Safety and Care Transitions"] There are various well documented success stories on medsync campaigns that said there is a gap between utilizing automation to increase efficiency while still providing proper patient care. MarkeTouch Media has bridged the gap by providing a proactive high touch approach that includes automation and live interactions. The solution can easily be utilized at stores, corporate, or by a call center. A multifaceted approach is easy to use for pharmacy staff, seamless to the patient, and functional reporting to the chain. Optimum MedSync brings an integrated clinical solution to the retail marketplace that allows clients to articu- late results in a meaningful manner. For more information, visit MarkeTouch Media at booth 3017 or online at www.rxtouch.com. leading the charge in addressing subop- timal medicines use with numerous intervention programs designed to drive patient engagement, stakeholder integration, cost reductions, and improved outcomes. These programs often involve expanded advisory serv- ices focused on chronic diseases and enhanced interactions between pharma- cists and patients. Over the next several years, the use of medicines is expected to increase due to expansion of insurance coverage, and rising incidence and prevalence of chron- ic disease and population aging. This places an even greater importance on IMS Health (Cont'd. from p. 4) ensuring those medicines are being used appropriately. A new report by the IMS Institute identifies actions that all healthcare stakeholders can take to help address the avoidable costs incurred when med- ications are not used according to the best evidence-based practices. To access the full report, visit the IMS Institute section of www.imshealth.com and be sure to check out the new app version of the report in iTunes at https://itunes.apple.com/us/app/ims- institute/id625347542. For more information, visit booth 2125 or contact IMS Health at www.imshealth.com or 610-244-2000.